
SNTI Stock Forecast & Price Target
SNTI Analyst Ratings
Bulls say
Senti Biosciences is actively pursuing its goal to develop innovative cell and gene therapies for patients with incurable diseases. In addition to promising data from their ongoing Phase 1 clinical trial for SENTI-202, the company has also seen positive results from its gene circuit platform, particularly with Donor X phenotype. While financing remains a risk, our financial analysis suggests the potential for significant future revenues with an aggressive expansion strategy.
Bears say
Senti Biosciences is a biotech company with a promising product in SENTI-202, but they face several challenges and risks that may hinder their potential for success. With regulatory unknowns and potential toxicities, as well as financial uncertainties, the company's future value and success depend heavily on the launch and adoption of their product in the market. Additionally, competition and manufacturing challenges add further risks to their outlook.
This aggregate rating is based on analysts' research of Senti Biosciences Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
SNTI Analyst Forecast & Price Prediction
Start investing in SNTI
Order type
Buy in
Order amount
Est. shares
0 shares